[go: up one dir, main page]

PL1651234T3 - Kompozycja antagonisty mGluR2 i inhibitora AChE do leczenia ostrych i/lub przewlekłych zaburzeń neurologicznych - Google Patents

Kompozycja antagonisty mGluR2 i inhibitora AChE do leczenia ostrych i/lub przewlekłych zaburzeń neurologicznych

Info

Publication number
PL1651234T3
PL1651234T3 PL04741126T PL04741126T PL1651234T3 PL 1651234 T3 PL1651234 T3 PL 1651234T3 PL 04741126 T PL04741126 T PL 04741126T PL 04741126 T PL04741126 T PL 04741126T PL 1651234 T3 PL1651234 T3 PL 1651234T3
Authority
PL
Poland
Prior art keywords
acute
treatment
combination
neurological disorders
chronic neurological
Prior art date
Application number
PL04741126T
Other languages
English (en)
Inventor
Theresa Maria Ballard
Mcarthur Silvia Gatti
Erwin Goetschi
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34130033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1651234(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL1651234T3 publication Critical patent/PL1651234T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL04741126T 2003-07-25 2004-07-17 Kompozycja antagonisty mGluR2 i inhibitora AChE do leczenia ostrych i/lub przewlekłych zaburzeń neurologicznych PL1651234T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03016968 2003-07-25
PCT/EP2004/008020 WO2005014002A1 (en) 2003-07-25 2004-07-17 Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
EP04741126A EP1651234B1 (en) 2003-07-25 2004-07-17 Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders

Publications (1)

Publication Number Publication Date
PL1651234T3 true PL1651234T3 (pl) 2008-02-29

Family

ID=34130033

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04741126T PL1651234T3 (pl) 2003-07-25 2004-07-17 Kompozycja antagonisty mGluR2 i inhibitora AChE do leczenia ostrych i/lub przewlekłych zaburzeń neurologicznych

Country Status (27)

Country Link
US (1) US7235547B2 (pl)
EP (1) EP1651234B1 (pl)
JP (1) JP5005343B2 (pl)
KR (1) KR100764330B1 (pl)
CN (1) CN1856312A (pl)
AR (1) AR045926A1 (pl)
AT (1) ATE374030T1 (pl)
AU (1) AU2004262897B9 (pl)
BR (1) BRPI0412919A (pl)
CA (1) CA2532347C (pl)
CO (1) CO5640124A2 (pl)
DE (1) DE602004009195T2 (pl)
DK (1) DK1651234T3 (pl)
ES (1) ES2293287T3 (pl)
HR (1) HRP20070552T3 (pl)
IL (1) IL173131A (pl)
MX (1) MXPA06000705A (pl)
MY (1) MY138394A (pl)
NO (1) NO20060328L (pl)
NZ (1) NZ544719A (pl)
PL (1) PL1651234T3 (pl)
PT (1) PT1651234E (pl)
RU (1) RU2357734C2 (pl)
SI (1) SI1651234T1 (pl)
TW (1) TW200524614A (pl)
WO (1) WO2005014002A1 (pl)
ZA (1) ZA200600693B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) * 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US8114894B2 (en) * 2008-12-03 2012-02-14 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8541404B2 (en) * 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
RU2472475C2 (ru) * 2010-04-20 2013-01-20 Учреждение образования "Белорусский государственный медицинский университет" (УО БГМУ) Способ комбинированного лечения глаукомной оптической нейропатии
AR093077A1 (es) 2012-10-23 2015-05-20 Hoffmann La Roche ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS
JP2017513844A (ja) 2014-04-23 2017-06-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 知的障害の処置のためのｍＧｌｕ２／３アンタゴニスト
CN112462047B (zh) * 2020-11-13 2023-02-07 北京元恩生物技术有限公司 一种尼卡巴嗪检测试剂盒及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2002518480A (ja) * 1998-06-22 2002-06-25 ニューロサーチ、アクティーゼルスカブ ５−又は８−ブロモイソキノリン誘導体の製造方法
US6194403B1 (en) * 1999-09-09 2001-02-27 Unitech Pharmaceuticals, Inc. Tacrine derivatives for treating Alzheimer's disease
DK1224174T3 (da) * 1999-10-15 2004-01-26 Hoffmann La Roche Benzodiazepinderivater
NZ518037A (en) * 1999-10-15 2004-04-30 F Benzodiazepine derivatives useful as metabotropic glutamate receptors
CA2310926C (en) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
EP1203584A1 (en) 2000-10-13 2002-05-08 M.D.M. S.r.l. Cholinergic precursor (in particular choline alfoscerate) associated with an acetylcholinesterase inhibitor (such as rivastigmine, donepezil)
US6500972B2 (en) * 2001-01-03 2002-12-31 Chinese Petroleim Corp. Synthesis of TMBQ with transition metal-containing molecular sieve as catalysts
US6500955B1 (en) * 2001-02-02 2002-12-31 National Institute Of Pharmaceutical Education And Research One pot synthesis of [2,8-Bis (trifluoromethyl)-4-quinolinyl]-2-pyridinylmethanone, a mefloquine intermediate
WO2002083662A2 (en) * 2001-04-09 2002-10-24 Fuji Photo Film Co., Ltd. Azo compounds and process of producing the same and novel intermediate compounds used in the process of producing azo compounds
HRP20030792A2 (en) * 2001-04-12 2005-10-31 F. Hoffmann - La Roche Ag DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
KR100566178B1 (ko) * 2001-04-12 2006-03-29 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ2 길항물질 Ｉ로서의디하이드로-벤조[ｂ][1,4]디아제핀-2-온 유도체
US6949542B2 (en) * 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives

Also Published As

Publication number Publication date
DE602004009195T2 (de) 2008-06-26
IL173131A0 (en) 2006-06-11
RU2006105721A (ru) 2007-09-10
AU2004262897B2 (en) 2009-08-20
CA2532347C (en) 2012-03-27
HRP20070552T3 (en) 2008-05-31
NO20060328L (no) 2006-02-17
TW200524614A (en) 2005-08-01
MY138394A (en) 2009-05-29
ATE374030T1 (de) 2007-10-15
US20050049243A1 (en) 2005-03-03
AU2004262897B9 (en) 2009-12-17
NZ544719A (en) 2009-04-30
AU2004262897A1 (en) 2005-02-17
MXPA06000705A (es) 2006-04-11
CN1856312A (zh) 2006-11-01
KR100764330B1 (ko) 2007-10-05
IL173131A (en) 2010-12-30
RU2357734C2 (ru) 2009-06-10
DK1651234T3 (da) 2008-01-28
PT1651234E (pt) 2007-12-28
JP2007504096A (ja) 2007-03-01
SI1651234T1 (sl) 2008-02-29
AR045926A1 (es) 2005-11-16
DE602004009195D1 (de) 2007-11-08
EP1651234A1 (en) 2006-05-03
ES2293287T3 (es) 2008-03-16
BRPI0412919A (pt) 2006-09-26
WO2005014002A1 (en) 2005-02-17
US7235547B2 (en) 2007-06-26
CO5640124A2 (es) 2006-05-31
EP1651234B1 (en) 2007-09-26
ZA200600693B (en) 2007-05-30
JP5005343B2 (ja) 2012-08-22
CA2532347A1 (en) 2005-02-17
KR20060037404A (ko) 2006-05-03

Similar Documents

Publication Publication Date Title
IL173131A0 (en) Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
IL210090A0 (en) TREATMENT OF TNFa RELATED DISORDERS
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
ZA200603221B (en) Triaza-spiropiperidine derivatives for use as GlyT-1 inhibitors in the treatment of neurological and neuropsychiatric disorders
IL162838A0 (en) Compositions and methods for prevention and treatment peptide-of amyloid- related disorders
ZA200700223B (en) Quinazolin-4-yl-piperidine and cinnolin-4-yl-peperidine derivatives as PDE10 inhibitors for the treatment of CNS disorders
SI1487541T1 (sl) Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
ZA200706238B (en) Prevention and treatment of thromboembolic disorders
IL181706A0 (en) The treatment of inflammatory disorders and pain
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
IL192694A0 (en) Combination of ache inhibitor and 5-ht6 antagonist for the treatment of cognitive dysfunction
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
ZA200600176B (en) Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
NO20054913D0 (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
ZA200705083B (en) Use of a 5-HT6 agonist for the treatment and prevention of neurodegenerative disorders
ZA200800981B (en) Use of SDF-1 for the treatment and/or prevention of neurological diseases
EP1812009A4 (en) GABA-STEROID ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF DISEASES OF THE CNS
GB0419828D0 (en) The treatment of inflammatroy disorders and pain
IL165870A0 (en) Use of chymase inhibitors for the prevention and/or
ZA200704412B (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
IL190842A0 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
ZA200508341B (en) Agents for the treatment of lower abdominal disorders
HK1107564A (en) Indenyl derivatives and use thereof for the treatment of neurological disorders